MCID: LNG017
MIFTS: 51

Lung Giant Cell Carcinoma

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Lung Giant Cell Carcinoma

MalaCards integrated aliases for Lung Giant Cell Carcinoma:

Name: Lung Giant Cell Carcinoma 12 15 17
Carcinoma, Giant Cell 44 70
Giant Cell Carcinoma of Lung 70
Giant Cell Lung Carcinoma 12
Giant Cell Carcinoma 12
Carcinoma Giant Cell 54

Classifications:



External Ids:

Disease Ontology 12 DOID:5583
MeSH 44 D018286
NCIt 50 C3779 C4452
SNOMED-CT 67 254631008 42596004
UMLS 70 C0206703 C0345960

Summaries for Lung Giant Cell Carcinoma

Disease Ontology : 12 A lung carcinoma that is located in large undifferentiated cells.

MalaCards based summary : Lung Giant Cell Carcinoma, also known as carcinoma, giant cell, is related to endometrial adenocarcinoma and transitional cell carcinoma, and has symptoms including fever, dyspnea and hemoptysis. An important gene associated with Lung Giant Cell Carcinoma is CXCL8 (C-X-C Motif Chemokine Ligand 8), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Ipilimumab and nivolumab have been mentioned in the context of this disorder. Affiliated tissues include large undifferentiated cells, lung and pancreas, and related phenotypes are Reduced mammosphere formation and growth/size/body region

Related Diseases for Lung Giant Cell Carcinoma

Diseases related to Lung Giant Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 302)
# Related Disease Score Top Affiliating Genes
1 endometrial adenocarcinoma 30.0 VEGFA CDKN2A CDH1
2 transitional cell carcinoma 29.7 NME1 MMP9 KRT18 CDKN2A CDH1
3 carcinosarcoma 29.7 VIM CDKN2A CDH1
4 hydronephrosis 29.6 VEGFA TIMP1 MMP9 CXCL8
5 angiosarcoma 29.4 VIM VEGFA MYC
6 pancreatic adenocarcinoma 29.3 VEGFA TIMP1 MMP9 MMP2 CDKN2A
7 liposarcoma 29.2 VIM MYC CDKN2A
8 adenocarcinoma 28.9 VEGFA MYC MMP9 MMP2 CDKN2A CDH1
9 rhabdomyosarcoma 28.9 VIM VEGFA MYC MMP2 CDKN2A
10 melanoma, uveal 28.9 VEGFA NME1 MYC MMP2 CDKN2A
11 lung cancer susceptibility 3 28.6 VEGFA MYC MMP9 MMP2 CDKN2A CDH1
12 endometrial cancer 28.3 VEGFA TIMP1 NME1 MYC MMP9 MMP2
13 pancreatic cancer 28.3 VEGFA MYC MMP9 MMP2 CXCL8 CDKN2A
14 melanoma 27.4 VIM VEGFA TIMP1 NME1 MYC MMP9
15 prostate cancer 27.1 VEGFA NME1 MYC MMP9 MMP2 KRT18
16 baritosis 10.3 TIMP1 CXCL8
17 autoimmune inner ear disease 10.3 TIMP1 MMP9
18 esophageal adenosquamous carcinoma 10.3 KRT18 CDH1
19 epstein-barr virus-associated gastric carcinoma 10.3 CDKN2A CDH1
20 vulvar intraepithelial neoplasia 10.3 CDKN2A CDH1
21 esophagus verrucous carcinoma 10.3 CDKN2A CDH1
22 maxillary sinus benign neoplasm 10.3 CDKN2A CDH1
23 fungal keratitis 10.3 TIMP1 MMP9
24 extracranial arteriovenous malformation 10.3 MMP9 MMP2
25 focal myositis 10.3 MMP9 MMP2
26 large cell carcinoma 10.2
27 rare tumor 10.2
28 spastic entropion 10.2 MMP9 MMP2
29 cardiac rupture 10.2 MMP9 CXCL8
30 middle ear squamous cell carcinoma 10.2 MMP9 CDKN2A
31 nasal cavity squamous cell carcinoma 10.2 MMP9 MMP2
32 light chain deposition disease 10.2 MMP9 MMP2
33 senile ectropion 10.2 MMP9 MMP2
34 mycetoma 10.2 MMP9 CXCL8
35 keratinizing squamous cell carcinoma 10.2 CDKN2A CDH1
36 severe nonproliferative diabetic retinopathy 10.2 VEGFA CXCL8
37 hypertrophic scars 10.2 TIMP1 MMP2
38 nasal cavity benign neoplasm 10.2 MMP9 MMP2
39 cryptogenic organizing pneumonia 10.2 TIMP1 MMP9 CXCL8
40 gingival disease 10.2 TIMP1 MMP9 CXCL8
41 primary peritoneal carcinoma 10.2 VEGFA CXCL8
42 infiltrating angiolipoma 10.2 VEGFA CDKN2A
43 gingival overgrowth 10.2 TIMP1 MMP2 CXCL8
44 pyelonephritis 10.2 TIMP1 MMP9 CXCL8
45 bronchiolitis obliterans 10.2 TIMP1 MMP9 CXCL8
46 middle ear carcinoma 10.2 MMP9 CDKN2A
47 bacterial meningitis 10.2 TIMP1 MMP9 CXCL8
48 cholecystitis 10.2 KRT18 CDKN2A CDH1
49 gingivitis 10.2 TIMP1 MMP9 CXCL8
50 hypopharynx cancer 10.1 NME1 CDKN2A CDH1

Graphical network of the top 20 diseases related to Lung Giant Cell Carcinoma:



Diseases related to Lung Giant Cell Carcinoma

Symptoms & Phenotypes for Lung Giant Cell Carcinoma

UMLS symptoms related to Lung Giant Cell Carcinoma:


fever; dyspnea; hemoptysis; coughing

GenomeRNAi Phenotypes related to Lung Giant Cell Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.28 CDH1 CXCL8 IL6R KRT18 MMP2 MYC

MGI Mouse Phenotypes related to Lung Giant Cell Carcinoma:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.25 CDH1 CDKN2A GJA1 IL6R KRT18 MMP2
2 homeostasis/metabolism MP:0005376 10.22 CDH1 CDKN2A GJA1 IL6R MMP2 MMP9
3 mortality/aging MP:0010768 10.22 CDH1 CDKN2A GJA1 IL6R KRT18 MMP2
4 cardiovascular system MP:0005385 10.2 CDH1 CDKN2A GJA1 MMP2 MMP9 MYC
5 immune system MP:0005387 10.2 CDH1 CDKN2A GJA1 IL6R MMP2 MMP9
6 cellular MP:0005384 10.19 CDH1 CDKN2A GJA1 IL6R MMP9 MTSS1
7 hematopoietic system MP:0005397 10.19 CDKN2A GJA1 IL6R MMP2 MMP9 MTSS1
8 endocrine/exocrine gland MP:0005379 10.13 CDH1 CDKN2A GJA1 IL6R MYC NME1
9 neoplasm MP:0002006 10.02 CDH1 CDKN2A IL6R MMP2 MMP9 MTSS1
10 liver/biliary system MP:0005370 9.98 CDKN2A IL6R KRT18 MTSS1 MYC NME1
11 muscle MP:0005369 9.91 CDKN2A GJA1 MMP2 MMP9 MYC VEGFA
12 normal MP:0002873 9.8 CDH1 GJA1 IL6R MMP2 MYC VEGFA
13 reproductive system MP:0005389 9.76 CDH1 CDKN2A GJA1 MMP9 MYC TIMP1
14 respiratory system MP:0005388 9.5 CDKN2A GJA1 MMP2 MMP9 TIMP1 VEGFA
15 skeleton MP:0005390 9.23 CDKN2A GJA1 MMP2 MMP9 MTSS1 MYC

Drugs & Therapeutics for Lung Giant Cell Carcinoma

Drugs for Lung Giant Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 6)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ipilimumab Approved Phase 2 477202-00-9
2
nivolumab Approved Phase 2 946414-94-4
3 Antineoplastic Agents, Immunological Phase 2
4 Antibodies Phase 2
5 Immunoglobulins Phase 2
6 Antibodies, Monoclonal Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
2 Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma Terminated NCT00568906

Search NIH Clinical Center for Lung Giant Cell Carcinoma

Cochrane evidence based reviews: carcinoma, giant cell

Genetic Tests for Lung Giant Cell Carcinoma

Anatomical Context for Lung Giant Cell Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Lung Giant Cell Carcinoma:

19
Large Undifferentiated Cells

MalaCards organs/tissues related to Lung Giant Cell Carcinoma:

40
Lung, Pancreas, Skeletal Muscle, Myeloid

Publications for Lung Giant Cell Carcinoma

Articles related to Lung Giant Cell Carcinoma:

(show top 50) (show all 63)
# Title Authors PMID Year
1
[Expression of connexin 43 in lung cancer and its correlation with E-cadherin]. 54 61
16834907 2006
2
Effect of interleukin-6 on the growth of human lung cancer cell line. 61 54
10374431 1998
3
Extremely Aggressive Behavior of a Completely Resected Case of Gallbladder Undifferentiated Carcinoma, Giant Cell Type: a Rare Case with Breast, Neck Nodes, and Subcutaneous Scalp Nodules Metastasis. 61
31155696 2020
4
Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas diagnosed by endoscopic ultrasound guided biopsy. 61
32863866 2020
5
Approaches to Tumor Classification in Pulmonary Sarcomatoid Carcinoma. 61
31824199 2019
6
[Current Status of Diagnosis and Treatment of Pulmonary Sarcomatoid Carcinoma]. 61
30591097 2018
7
A Rare Case of Sarcomatoid Carcinoma of the Lung with Spine Metastasis, Including a Literature Review. 61
28684728 2017
8
Epidemiological features of lung giant cell carcinoma and therapy for patients with EGFR mutations based on case reports and the surveillance, epidemiology, and end results (SEER) database. 61
28445978 2017
9
Missing in metastasis B, regulated by DNMT1, functions as a putative cancer suppressor in human lung giant-cell carcinoma. 61
28159994 2017
10
[Pulmonary sarcomatoid carcinoma]. 61
26778815 2016
11
A case of long-term 24-month survival in pancreatic anaplastic carcinoma (giant cell type) after S1 postoperative adjuvant chemotherapy. 61
27111877 2016
12
[Sarcomatoid carcinoma of the lung: retrospective study of 28 cases]. 61
24703022 2014
13
A case report of anaplastic carcinoma of the pancreas with remarkable intraductal tumor growth into the main pancreatic duct. 61
24574758 2014
14
Pulmonary sarcomatoid carcinoma: a clinicopathologic study and prognostic analysis of 51 cases. 61
24088577 2013
15
[Pulmonary sarcomatoid carcinoma]. 61
22889810 2012
16
Sarcomatoid neoplasms of the lung and pleura. 61
21043818 2010
17
Review article: pulmonary sarcomatoid carcinomas: a practical overview. 61
19124452 2010
18
[PAR-1 regulation of intracellular Ca²(+) mobilization in pulmonary giant cell carcinoma cell line PLA801D/PLA801C]. 61
20388375 2010
19
[A case of carcinosarcoma in the liver]. 61
19835222 2009
20
Undifferentiated giant cell type carcinoma of the gallbladder with sarcomatoid dedifferentiation: a case report and review of the literature. 61
19830109 2009
21
[Two cases of anaplastic carcinoma of the pancreas in terms of the diversity of carcinoma cells (epithelial-mesenchymal transition; EMT)]. 61
18987452 2008
22
[Expression and clinical significance of RhoC and RhoGDIa in non-small cell lung cancer.]. 61
20731941 2008
23
[Functional aspects of protease-activated receptor 1 in promoting metastasis of lung cancer]. 61
17706138 2007
24
A case of anaplastic ductal carcinoma of the pancreas with production of granulocyte-colony stimulating factor. 61
17153462 2006
25
Establishment and characterization of a human thyroid carcinoma cell line (HOTHC) producing colony stimulating factor. 61
17022149 2005
26
[A case of anaplastic ductal carcinoma (giant cell carcinoma of osteoclastoid type) with portal vein and main pancreatic ductal invasion]. 61
15981633 2005
27
Effective asymmetry in gap junctional intercellular communication between populations of human normal lung fibroblasts and lung carcinoma cells. 54
14656943 2004
28
[Identification of novel metastasis associated genes MAG-1 and MAG-2]. 61
21310131 2003
29
[Study on differentially expressed molecules influencing the metastatic potential between highly and poorly metastatic human lung giant cell carcinoma]. 61
14690554 2003
30
[Function of IL-18 in promoting metastasis of lung cancer]. 61
12921563 2003
31
Large cell neuroendocrine carcinoma of the urinary bladder with lymphoepithelioma-like features. 61
14533941 2003
32
Experimental study on mechanism and rarity of metastases in skeletal muscle. 61
12609079 2002
33
cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis. 61
11410166 2001
34
[Regulatory effect of antisense VEGF121 cDNA transfection on angiogenesis and metastasis of human lung giant cell carcinoma]. 61
11236636 2000
35
An assessment of the aggressive potential of radiolucencies related to the mandibular molar teeth. 61
10767189 2000
36
Pleomorphic giant cell carcinoma of the esophagus with coexpression of cytokeratin and vimentin and neuroendocrine differentiation. 54
10629146 2000
37
[Pathological and immunohistochemical analysis of giant cells of pancreas]. 54
9391326 1997
38
[Differential expression and response of growth factors in metastatic variants of human pulmonary giant cell carcinoma cell line]. 54
10072879 1997
39
[Influence of transfection of sense- and antisense-TGF beta 1 gene on human pulmonary giant cell carcinoma cell proliferation]. 54
10743067 1997
40
[Growth regulatory mechanisms of recombinant human interleukin-6 on human lung carcinoma cell lines]. 61
9596958 1997
41
[Interleukin-6 behaves as an autocrine growth stimulator for a human lung giant cell carcinoma cell line]. 61
10072840 1997
42
[Mutation of P53 gene in a highly metastatic human lung cancer cell line]. 61
7587895 1995
43
[Isolation and characterization of human lung cancer cell subline with different metastatic potential]. 61
7656376 1995
44
[Effects of metalloproteinases-1 (TIMP-1) cDNA transfection on biological behaviors of PG cells]. 54
7987710 1994
45
[Studies on the reduction of malignant phenotypes in a highly metastatic human lung carcinoma--correlated changes of intercellular communication, cytoskeletons, oncogenes and antioncogene]. 61
7924870 1994
46
Selective effect of O-alkyl lysophospholipids on the growth of a human lung giant cell carcinoma cell line. 61
8017834 1994
47
Characterization of a 64-kd protein phosphorylated during chemotactic activation with IL-8 and fMLP of human polymorphonuclear leukocytes. II. Purification and amino acid analysis of phosphorylated 64-kd protein. 61
8336074 1993
48
Characterization of a 64-kd protein phosphorylated during chemotactic activation with IL-8 and fMLP of human polymorphonuclear leukocytes. I. Phosphorylation of a 64-kd protein and other proteins. 61
8393062 1993
49
Isolation and amino acid sequence of a chemotactic protein, LECT/interleukin 8, from a human myeloid leukemia cell line, ML-1. 61
8344717 1993
50
Unusual forms of carcinoma of the urinary bladder. 61
1842384 1991

Variations for Lung Giant Cell Carcinoma

Cosmic variations for Lung Giant Cell Carcinoma:

9 (show top 50) (show all 1546)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM102042323 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.-23-8009A>G p.? 16:72958974-72958974 12
2 COSM87291734 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1172A>G p.Q391R 16:72958974-72958974 12
3 COSM102040476 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.-23-8037G>T p.? 16:72959002-72959002 12
4 COSM149314749 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1144G>T p.G382C 16:72959002-72959002 12
5 COSM87290218 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1144G>T p.G382C 16:72959002-72959002 12
6 COSM149318860 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1172A>G p.Q391R 16:72958974-72958974 12
7 COSM126973051 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.770C>T p.P257L 11:102229729-102229729 12
8 COSM145028029 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1154C>T p.P385L 11:102229729-102229729 12
9 COSM128452039 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1142C>T p.P381L 11:102229729-102229729 12
10 COSM85237448 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1304C>T p.P435L 11:102229729-102229729 12
11 COSM143041512 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1316C>T p.P439L 11:102229729-102229729 12
12 COSM127997731 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1256C>T p.P419L 11:102229729-102229729 12
13 COSM133274224 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1268C>T p.P423L 11:102229729-102229729 12
14 COSM90948266 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1202C>T p.P401L 11:102229729-102229729 12
15 COSM108017622 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1009A>C p.I337L 22:41653558-41653558 12
16 COSM95166535 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 12
17 COSM97230831 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 12
18 COSM105839764 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1009A>C p.I337L 22:41653558-41653558 12
19 COSM106337415 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 12
20 COSM103711109 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1036A>C p.I346L 22:41653558-41653558 12
21 COSM85312404 XRCC1 lung,NS,carcinoma,undifferentiated carcinoma c.1207A>G p.M403V 19:43546970-43546970 12
22 COSM134125623 XRCC1 lung,NS,carcinoma,undifferentiated carcinoma c.1114A>G p.M372V 19:43546970-43546970 12
23 COSM100781761 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.724A>T p.K242* 11:32392044-32392044 12
24 COSM111539040 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1309A>T p.K437* 11:32392044-32392044 12
25 COSM149728755 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 12
26 COSM130518653 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.673A>T p.K225* 11:32392044-32392044 12
27 COSM113475703 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 12
28 COSM111529696 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 12
29 COSM113484991 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 12
30 COSM147414475 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 12
31 COSM149739953 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 12
32 COSM148580942 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 12
33 COSM148593279 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 12
34 COSM91372655 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 12
35 COSM91383011 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 12
36 COSM147426277 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1309A>T p.K437* 11:32392044-32392044 12
37 COSM124478343 WNT8A lung,NS,carcinoma,undifferentiated carcinoma c.422G>C p.G141A 5:138088927-138088927 12
38 COSM104050903 WNT8A lung,NS,carcinoma,undifferentiated carcinoma c.368G>C p.G123A 5:138088927-138088927 12
39 COSM105123686 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.*288A>C p.? 12:48966259-48966259 12
40 COSM87652733 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.1006A>C p.K336Q 12:48966259-48966259 12
41 COSM102763785 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.*288A>C p.? 12:48966259-48966259 12
42 COSM99767946 USP5 lung,NS,carcinoma,undifferentiated carcinoma c.755C>T p.T252I 12:6856877-6856877 12
43 COSM84601598 USP5 lung,NS,carcinoma,undifferentiated carcinoma c.755C>T p.T252I 12:6856877-6856877 12
44 COSM121848752 USP38 lung,NS,carcinoma,undifferentiated carcinoma c.994G>C p.A332P 4:143197868-143197868 12
45 COSM88410243 USP38 lung,NS,carcinoma,undifferentiated carcinoma c.994G>C p.A332P 4:143197868-143197868 12
46 COSM87541563 USP32 lung,NS,carcinoma,undifferentiated carcinoma c.192T>A p.I64= 17:60301699-60301699 12
47 COSM99795256 USP32 lung,NS,carcinoma,undifferentiated carcinoma c.192T>A p.I64= 17:60301699-60301699 12
48 COSM143996084 UHRF1 lung,NS,carcinoma,undifferentiated carcinoma c.1620C>G p.F540L 19:4947122-4947122 12
49 COSM143964403 UHRF1 lung,NS,carcinoma,undifferentiated carcinoma c.1428C>G p.F476L 19:4947122-4947122 12
50 COSM145430147 UHRF1 lung,NS,carcinoma,undifferentiated carcinoma c.1467C>G p.F489L 19:4947122-4947122 12

Expression for Lung Giant Cell Carcinoma

Search GEO for disease gene expression data for Lung Giant Cell Carcinoma.

Pathways for Lung Giant Cell Carcinoma

Pathways related to Lung Giant Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 VIM VEGFA TIMP1 MYC MMP9 MMP2
2
Show member pathways
13.68 VIM VEGFA TIMP1 MYC KRT18 IL6R
3
Show member pathways
13.22 VIM VEGFA TIMP1 MYC MMP9 MMP2
4
Show member pathways
12.81 VEGFA MYC IL6R CXCL8 CDKN2A
5
Show member pathways
12.74 VEGFA MYC MMP9 CDKN2A CDH1
6
Show member pathways
12.57 MMP9 MMP2 CDKN2A CDH1
7
Show member pathways
12.56 VEGFA MMP9 MMP2 KRT18
8 12.48 VEGFA MYC MMP9 MMP2 IL6R CXCL8
9 12.43 VIM VEGFA MYC MMP9 CDKN2A
10 12.41 VIM MTSS1 KRT18 GJA1 CDH1
11 12.2 VEGFA MYC MMP9 MMP2
12 12.09 VEGFA IL6R GJA1 CXCL8
13 11.99 VEGFA MMP9 MMP2
14 11.99 VIM VEGFA MYC GJA1
15 11.95 VEGFA MYC MMP9 MMP2 IL6R CDH1
16 11.94 MMP9 MMP2 GJA1 CDH1
17 11.88 VIM MYC MMP9 GJA1 CXCL8
18 11.86 VEGFA TIMP1 IL6R
19 11.84 IL6R CXCL8 CDKN2A
20 11.81 VEGFA MMP2 CXCL8
21
Show member pathways
11.8 TIMP1 MMP9 MMP2
22 11.75 TIMP1 MMP9 MMP2
23
Show member pathways
11.72 TIMP1 MYC IL6R
24 11.69 NME1 MYC MMP9
25 11.62 MYC MMP9 MMP2 CXCL8 CDH1
26
Show member pathways
11.6 VEGFA MMP9 MMP2 CXCL8
27 11.58 MMP9 MMP2 CXCL8
28 11.58 TIMP1 MMP9 MMP2 CXCL8
29 11.54 TIMP1 MMP9 MMP2 CXCL8
30
Show member pathways
11.51 MYC MMP9 MMP2
31 11.44 VEGFA MYC IL6R CXCL8
32 11.36 VEGFA MYC MMP9 MMP2 CXCL8 CDKN2A
33 11.28 VIM VEGFA TIMP1 MYC MMP9 MMP2
34 11.2 MMP9 MMP2 GJA1 CXCL8
35 10.94 VEGFA TIMP1
36 10.91 VIM CDH1

GO Terms for Lung Giant Cell Carcinoma

Cellular components related to Lung Giant Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 VEGFA TIMP1 MMP9 MMP2 KRT18 IL6R
2 extracellular matrix GO:0031012 8.92 VEGFA TIMP1 MMP9 MMP2

Biological processes related to Lung Giant Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.8 VEGFA TIMP1 MYC MMP9 KRT18
2 cell cycle arrest GO:0007050 9.69 MYC CXCL8 CDKN2A
3 positive regulation of gene expression GO:0010628 9.63 VIM VEGFA MYC GJA1 CXCL8 CDKN2A
4 extracellular matrix disassembly GO:0022617 9.54 TIMP1 MMP9 MMP2
5 positive regulation of epithelial cell proliferation GO:0050679 9.5 VEGFA NME1 MYC
6 positive regulation of DNA biosynthetic process GO:2000573 9.49 VEGFA MYC
7 response to amyloid-beta GO:1904645 9.48 MMP9 MMP2
8 induction of positive chemotaxis GO:0050930 9.46 VEGFA CXCL8
9 negative regulation of trophoblast cell migration GO:1901164 9.43 TIMP1 GJA1
10 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.43 MMP9 MMP2 GJA1
11 cytokine-mediated signaling pathway GO:0019221 9.23 VIM VEGFA TIMP1 MYC MMP9 MMP2
12 cellular response to UV-A GO:0071492 9.13 TIMP1 MMP9 MMP2

Sources for Lung Giant Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....